通过常规临床数据和IL-6:朝着个性化抗炎疗法预测重症患者的超炎症表型
Charlotte Linz1,2, Alexander Shimabukuro-Vornhagen1,2, Nina Hesse1,2
1Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.
International journal of molecular sciences
|October 29, 2025
概括
干白素-6 (IL-6) 在诸如败血症之类的危急疾病中升高. 高水平的IL-6,特别是在中性质减退的情况下,表明严重的炎症和改变患者的结果,建议向治疗.
科学领域:
- 关键护理医学 关键护理医学
- 免疫学 免疫学 免疫学
- 翻译研究是翻译研究.
背景情况:
- 洲际蛋白-6 (IL-6) 是系统性炎症的关键调解剂,在毒症和ARDS等严重疾病中经常升高.
- 患者对免疫调节疗法的不同反应需要更深入地了解IL-6调节和临床意义.
研究的目的:
- 在重症患者中研究IL-6调节的决定因素.
- 确定与IL-6水平和死亡率相关的临床和炎症表型.
- 探索IL-6在重症监护室 (ICU) 设置中的预后价值.
主要方法:
- 对ICU患者的回顾性分析具有全面的临床和实验室数据,包括血IL-6.
- 通过电化学发光免疫试验量化IL-6.
- 统计分析包括生存分析,拉索回归,贝叶斯逻辑回归和潜在类分析.
主要成果:
- 在败血症和中性缺陷症中,IL-6水平显著升高,当这两种情况并存时,IL-6度极高.
- 虽然IL-6不是ICU死亡率的普遍预测因素,但值 (≥200 pg/mL) 与生存率降低相关.
- 鉴定了一种高炎症表型 (IL-6 ≥100 pg/mL),与超过40%的预测死亡率和58%的观察死亡率相关,以及不同的患者亚组.
结论:
- 败血症和中性是严重疾病中IL-6升高的主要驱动因素.
- 以IL-6水平为特征的明显的炎症表型可以帮助风险分层.
- 这些发现支持了针对性抗细胞因子治疗在重症监护中的潜力.
更多相关视频
12:50Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
6.9K
07:48Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
Published on: May 16, 2016
12.1K
相关概念视频
Inflammatory Response
15.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
